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Recent studies describe a novel role of fibroblast growth
factor-23 (Fgf23)–klotho activity in the systemic regulation of
calcium and phosphate homeostasis. Both Fgf23 and klotho
ablated mice develop extensive vascular and soft tissue
calcification. Inability to clear the required amount of
phosphate by the kidney, due to the absence of Fgf23–klotho
activity, leads to increased accumulation of serum phosphate
in these genetically modified mice, causing extensive
calcification. Serum calcium and 1,25 hydroxyvitamin D levels
are also elevated in both Fgf23 and klotho ablated mice.
Moreover, increased sodium phosphate co-transporter
activity in both Fgf23 and klotho ablated mice increases renal
phosphate reabsorption which in turn can facilitate
calcification. Collectively, these observations bring new
insights into our understanding of the roles of the
Fgf23–klotho axis in the development of vascular and soft
tissue calcification.
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FIBROBLAST GROWTH FACTOR-23
Fibroblast growth factor-23 (FGF23) is an approximately
30-kDa secreted protein that is mostly synthesized by the
osteocytes in the bone.1,2 FGF23 is a master in vivo regulator
of phosphate homeostasis. Under physiological conditions, it
controls renal phosphate excretion according to the need of
the body through the regulation of the renal sodium-
dependent phosphate co-transporters NaPi2a and NaPi2c.3,4
Genetic defects in the FGF23 gene can produce distinct
human diseases. For instance, gain-of-function mutations in
FGF23 are responsible for the clinical symptoms observed in
patients suffering from autosomal dominant hypophospha-
temic rickets.5 These mutations prevent the proteolytic
cleavage of the FGF23 protein, leading to its increased
biological activity and resulting in severe renal phosphate
wasting. Similarly, increased serum levels of FGF23 in
patients with oncogenic osteomalacia are found to be the
causative factor for tumor-induced renal phosphate wasting.6
Patients affected by X-linked hypophosphatemia, a dominant
disorder caused by inactivating mutations of the gene
encoding PHEX (the phosphate-regulating gene with homo-
logies to endopeptidases on the X chromosome), exhibit
increased serum FGF23 levels, phosphaturia, and osteoma-
lacia.7 A similar phosphate wasting effect, due to increased
FGF23 serum levels, has been detected in patients with
autosomal recessive hypophosphatemia—a rare genetic dis-
order with essentially similar clinical features as those seen in
the patients with oncogenic osteomalacia, X-linked hypophos-
phatemia, and autosomal dominant hypophosphatemic
rickets.8,9 Recent studies using wild-type and autosomal domi-
nant hypophosphatemic rickets mutant proteins have identified
key FGF23-specific receptor-mediated signaling.10,11
FIBROBLAST GROWTH FACTOR-23 SIGNALING
FGF23 exerts its bioactivity on selected target tissues by
interacting with its cognate FGF receptors (FGFRs) in the
presence the cofactor klotho.10–12 The klotho gene encodes a
single-pass transmembrane protein with an extracellular
domain consisting of two homologous domains that share
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sequence homology with the b-glucosidase of bacteria and
plants. Klotho facilitates the binding of FGF23 to FGFR1c,
FGFR3c, and FGFR4.11,12 FGFRs contain a signal-transducing
extracellular ligand-binding domain and an intracellular
tyrosine kinase domain. The restricted expression of klotho
determines the tissue specificity of FGF23 function.12,13
Klotho is mostly expressed in the renal distal tubular
epithelial cells, the parathyroid gland, and the pituitary
gland.13,14
FGF23, in the presence of klotho, can activate downstream
signaling molecules, as determined by activation or phos-
phorylation of FGFR substrate-2a, extracellular signal-
regulated kinase, and early growth response element-1.10,11
Only in the presence of klotho, cells exposed to FGF23
underwent extracellular signal-regulated kinase phosphoryla-
tion and increased the expression of early growth response
element-1 protein. Klotho also enhances FGF23 binding to its
receptor because FGF23 has a greater affinity to the
Klotho–FGFR complex than to the FGFR alone, underscoring
the important role of klotho as a cofactor in the FGF23–FGFR
interaction and subsequent signaling.11 Our understanding of
FGF23 and its receptor interactions, along with the down-
stream signaling events, helps us focus on its biological
functions. Recent genetic studies by generating Fgf23- and
klotho-ablated mice, have shown that altered mineral ion
metabolism in the mutant mice is associated with extensive
vascular and soft tissue calcification.15–17
VASCULAR CALCIFICATION
Vascular calcification is a complex, regulated process that
involves the molecular interplay between calcification
stimulators and inhibitors. Although numerous individual
molecules and/or factors have been identified as stimulators
of calcification, including inorganic phosphate, calcium,
sodium phosphate co-transporters, Runx2, tissue nonspecific
alkaline phosphase (TNAP), glucose, acetylated LDL, tumor-
necrosis factor-a, and bone morphogenetic protein-2,18–20
their exact mechanism to induce vascular calcification and
their interaction with the calcification inhibitors is not yet
clearly understood.
Recent studies have shed some light on vascular calcifica-
tion and how a disrupted balance between calcification-
inhibiting and -promoting factors can lead to ectopic
calcification. As mentioned, there are several key factors that
have been shown to directly regulate the induction and
progression of vascular calcification; these include but are not
limited to circulating factors (eg, phosphate, calcium,
pyrophosphate, and parathyroid hormone) and their signal-
ing components, matrix molecules (eg, matrix Gla protein;
MGP), and catalyzing enzymes (eg, TNAP).
Serum phosphate and calcium levels are important
determinants of vascular calcification, as inadequate regula-
tion of these minerals can lead to spontaneous deposition of
calcium phosphate in the blood vessels and soft tissues.
Hyperphosphatemia in dialysis patients correlates with
vascular calcification, and effective phosphate control with
noncalcium phosphate binders is correlated with attenuated
progression of vascular calcification in these patients.21 In
addition, in vitro studies have shown that smooth muscle
cells grown in the presence of elevated inorganic phosphorus
undergo a dramatic phenotypic change characterized by the
downregulation of smooth muscle cell lineage genes and the
upregulation of the osteochondrogenic lineage genes.22
Similar to phosphorus, a positive calcium balance is linked
to vascular calcification in humans.23 In vitro, calcium
promotes mineralization in vascular smooth muscle cells,
and the calcium-induced mineralization upregulates the
expression of the major sodium-dependent phosphate co-
transporters in these cells.24
Inorganic pyrophosphate inhibits vascular calcification by
restricting hydroxyapatite formation and propagation
through its biophysical chelator-like role, as well as stabilizing
the aortic phenotype by acting as a paracrine regulator.19
Reduced plasma pyrophosphate levels are reported in
hemodialysis patients and are exacerbated as a result of
pyrophosphate clearance.25 It is therefore likely that restoring
pyrophosphate levels may help in limiting vascular calcifica-
tion. Another factor, TNAP, an enzyme produced in several
tissues including bones, serves as a functional phenotypic
marker of osteoblasts and is often used as a molecular marker
for vascular calcification. Because pyrophosphate is a
substrate for TNAP and phosphorus is the product of its
catalytic activity, one can theoretically anticipate that
upregulated TNAP expression acts as a precursor to vascular
calcification.26 Parathyroid hormone can also influence
vascular calcification. Uncontrolled secretion of parathyroid
hormone can release excessive amounts of calcium from
bone, which can precipitate as calcifying foci in blood vessels
and soft tissues.27
Bone morphogenetic protein-2 plays a role in calcification
by exerting osteogenic effects on blood vessels and soft
tissues.28 Studies have shown a positive correlation between
bone morphogenetic protein-2 and vascular calcification.
Furthermore, matrix proteins, like MGP can inhibit vascular
calcification. A positive correlation exists between the local
expression of MGP and calcification in arteries. In MGP
knockout mice and human Keutel syndrome, MGP defi-
ciency is associated with ectopic calcification.29 MGP is able
to control vascular calcification partly through its Gla
residues, which have a calcium/hydroxy apatite-chelating
capacity.
Vascular calcification is histologically divided into four
main types: (1) atherosclerotic intimal calcification, (2)
medial artery calcification (Monckeberg sclerosis), (3)
cardiac valve calcification, and (4) arteriole calcification in
the form of calciphylaxis. Although systemic factors have
great importance in inducing calcification, the interplay
between the resident cells of the vasculature usually
determines the extent of the damage; cross talks and
phenotypic alteration of endothelial cells, smooth muscle
cells, pericytes, and perhaps mesenchymal stem cells, in
response to systemic dysregulation of mineral balance can
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significantly influence the calcification process. In general,
there are significant similarities between skeletal mineraliza-
tion, and vascular and soft tissue calcification.28 The reader is
referred to recent reviews for an in-depth overview of the
general aspects of bone and vascular calcification.18,28 The
purpose of this review is to briefly discuss the potential effects
of FGF23–klotho activity on the development of vascular and
soft tissue calcification.
DOES FGF23–KLOTHO ACTIVITY INFLUENCE CALCIFICATION?
Both human and animal studies have shown that reduced
FGF23 or klotho activities are closely associated with vascular
and soft tissue calcification.
Animal studies
Extensive vascular and soft tissue calcification is observed in
Fgf23 knockout mice by 6 weeks of age; small and medium
sized arteries and the proximal tubules in the kidneys are the
most extensively affected sites, in addition to the aorta.
Interestingly, the expression of the sodium phosphate co-
transporter, NaPi2a of the proximal tubular epithelial cells is
also upregulated in Fgf23 knockout mice.1 Increased tubular
sodium phosphate co-transporter expression (Figure 1) in
these mice may translocate extracellular phosphate within the
cells to facilitate calcification. In addition to kidney and
blood vessels (Figure 2), Fgf23 knockout mice also exhibit
widespread soft tissue calcification in the lungs, skeletal
muscle, skin, urinary bladder, testes, and cardiac muscle.
Vascular and soft tissue calcification appear as early as
6 weeks postnatally and progress with age in Fgf23 knockout
mice.15,16 Such widespread calcification in Fgf23 knockout
mice is associated with osteopenia. Autoradiographic studies
of both fore and hind limbs show that the bone mineral
density (BMD) is strikingly reduced in Fgf23 knockout mice,
compared with their control littermates.1 Interestingly,
despite reduced BMD, the total body mineral content in
Fgf23 knockout mice is higher due to their extensive vascular
and soft tissue calcification.1,15 The Fgf23 knockout mouse
phenotype has clinical relevance, as human studies have also
shown an association between reduced BMD and vascular
calcification;30 low BMD is suggested to independently
predict coronary artery disease in women, with a higher
odds ratio than traditional risk factors.31 Lower BMD, yet
higher body mineral content in Fgf23 knockout mice,
therefore, provides a unique model to study molecular
regulation of osteoporosis and vascular calcification.1,15
Similar to the Fgf23 knockout animals, mice homozygous
for the hypomorphic alleles of the klotho gene show increased
expression of NaPi2a and NaPi2c co-transporters in the
proximal tubular epithelial cells (Figure 1). Furthermore,
extensive calcification in both vascular and soft tissues,
including lungs, skin, testis, and heart is noted in klotho-
ablated mice. Taking into consideration the phenotypes
of both Fgf23- and klotho-ablated mice, it seems likely that
in vivo dysregulation of the FGF23–klotho axis can lead
to vascular calcification, possibly by affecting mineral
ion metabolism.4,32–34 Needless to mention that extensive
vascular and soft tissue calcification in both Fgf23- and
klotho-ablated mice is associated with severe hyperphos-
phatemia, and increased serum level of 1,25 hydroxyvitamin
D.15–17 The experimental relevance of both Fgf23- and klotho-
ablated mice has significantly increased due to the fact that
mutations in either human FGF23 or Klotho genes are also
associated with ectopic calcification.
Human studies
In accord with the animal studies, human diseases associated
with inactivating mutations in either FGF23 or Klotho gene
Figure 1 | Expression of NaPi2a. Immunostaining of NaPi2a
protein in kidneys obtained from control (a), Fgf23/ (b), and
klotho/ (c) mice. An increased expression of NaPi2a protein
is detected in Fgf23/ and klotho/ mice, compared with
wild-type mice. Please note that NaPi2a protein is exclusively
present in the luminal side of the proximal tubular epithelial cells.
Figure 2 | Soft tissue and vascular calcification in Fgf23/
mice. von Kossa staining on paraffin sections of the kidney
(a, b) and lung (c, d), showing widespread renal (b) and
pulmonary (d) calcifications in Fgf23/ mice. No such calcification
is noted in the wild-type littermates (a, c). Arrows depict
the calcified vessels in the kidney and lung of the Fgf23/
mice (original magnification: kidney,  20; lung,  10).
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express severe ectopic calcification. For instance, familial
tumoral calcinosis is an autosomal recessive disorder
characterized by hyperphosphatemia and ectopic calcifica-
tion; and is associated with diaphysitis, hyperostosis,
arterial aneurysms, dental abnormalities, and angioid streaks
of the retina. Genetic studies have shown evidence that
missense mutations in the human FGF23 gene or GALNT3
gene (UDP-N-acetyl—a-D-galactosamine: polypeptide
N-acetylgalactosaminyltransferase-3) cause the disease.35
Mutations in GALNT3 prevent its ability to selectively
O-glycosylate a furin-like convertase recognition sequence
in FGF23, thus preventing the proteolytic processing of
FGF23 and the secretion of intact FGF23 protein.36 Hence,
mutations in either FGF23 or GALNT3 genes reduce FGF23
activities, which lead to hyperphosphatemia and eventually
to tumoral calcinosis in patients with familial tumoral
calcinosis.
Klotho is a recently identified cofactor in FGF23 signaling.
Experimental studies have demonstrated convincingly that
FGF23, in the absence of klotho, cannot exert its bioactivities.
For instance, despite extremely high serum levels of Fgf23
(about 2000-fold higher) in klotho-ablated mice, Fgf23 is
unable to exert its phosphaturic effects in these mice.12 The
lack of phosphaturic activity despite extremely high levels of
Fgf23 in klotho-ablated mice signifies that Fgf23 is incapable
to perform its physiological functions in the absence of
klotho.32 Recently, a point mutation in the human Klotho
gene was reported in a 13-year-old patient with severe
vascular and soft tissue calcification despite significantly high
serum level of FGF23. Lack of function of the Klotho gene
in this patient can attenuate the ability of FGF23 to exert
its phosphate-lowering effects, which can eventually lead to
the severe vascular and soft tissue calcifications.37
CAN FGF23 SUPPRESS CALCIFICATION?
Because reduced FGF23 activity is associated with vascular
and soft tissue calcification in both experimental and human
studies, the clinically relevant question would be that whether
FGF23 has any calcification inhibitory effects. Current
observations suggest that the manipulation of FGF23 activity
can delay calcification through the lowering of serum calcium
and phosphate levels. Also, Shimada et al.38 demonstrated
that FGF23 can suppress the renal expression of 1a-hydroxy-
lase, the rate-limiting enzyme that converts the inactive
vitamin D metabolite into its active form. It is possible that
FGF23 can reduce calcification by inhibiting vitamin D
activity. Inaba et al.39 recently reported that FGF23 is an
independent factor that is negatively associated with hand
artery, but not aortic calcification in hemodialysis patients,
and proposed plasma FGF23 levels as a reliable marker for
medial peripheral artery calcification in these patients.
Nevertheless, extensive cardiovascular calcification is the
leading cause of death in chronic kidney disease patients
undergoing dialysis, despite their significantly high serum
FGF23 levels.40–42 Variability in the degree of failing kidneys
can account for this apparent contradiction: diminishing
renal function interferes to various extents with the ability of
FGF23 to exert its inhibitory effects due to potential defects
in klotho and/or FGFR expression, leading to both elevated
serum FGF23 levels and vascular calcification. Finally, a
recent study on subjects with normal kidney function found
no correlation between serum intact FGF23 and/or fetuin-A
levels, and coronary artery score.43 These findings suggest
that under normal renal function, where the kidneys are
effectively maintaining a normal phosphate balance, FGF23 is
not a suitable marker for coronary artery calcification.
Further studies are needed to better understand the role of
FGF23 in vascular and soft tissue calcification under various
pathological conditions.
CONCLUSION
The recent understanding of the systemic regulation of
mineral ion homeostasis and vitamin D metabolism by
FGF23–klotho signaling leads us to revisit the mechanistic
aspect of calcification.44–47 Whether the FGF23/klotho can
directly inhibit calcification or whether the effect is indirect
due to reduced availability of calcification promoting mineral
ions needs additional study. Hypothetically, enhanced
FGF23–klotho activity can delay the process of calcification
by negatively impacting the serum phosphate balance. Further
studies will determine if the pharmacological manipulation
of FGF23 activity can be beneficial in fine-tuning existing
treatments of vascular and/or soft tissue calcification.48 Such
studies will also expand our understanding of the funda-
mental aspects of mineral ion metabolism under physiological
and pathological conditions, including calcification.
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